SHH and acute myeloid leukemia: In AML, the present study also demonstrated that the level of IL-6 and Shh were higher in AML patients than normal donors, and even higher IL-6 and Shh levels in patients who showed poor prognosis (such as poor quality of life, resistant to chemotherapy, and higher risk on life threat) and died from cancer.